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Aim: Premixed insulin regimens are commonly used for the treatment of patients with type-2 diabetes mellitus
(T2DM). However, limited data are available regarding next-step therapy options in cases where premixed insulin
fails to provide adequate glycemic control. This 20-week observational study of everyday clinical practice evaluated
the efficacy, safety and treatment satisfaction of insulin glargine plus oral anti-diabetic drugs (OADs) in T2DM
patients previously treated with premixed insulin.
Methods: In this open-label, single-arm, 20-week study, 70 subjects with T2DM inadequately controlled with premixed
insulin were switched to insulin glargine plus OADs. Changes in glycaemic control, incidence of hypoglycaemia,
treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), serum superoxide dismutase
(SOD), and serum 8-iso-prostaglandin (8-iso-PG) were evaluated at the start and the end of the study.
Results: Over the 20 week treatment period, mean (±SD) HbA1c levels decreased from 8.28 ± 1.24% to 6.83 ± 1.09%,
mean (±SD) FBG levels decreased from 7.64 ± 1.36 mmol/L to 5.57 ± 1.21 mmol/L, and 2 h PBG levels decreased
from 12.07 ± 1.17 mmol/L to 8.94 ± 1.56 mmol/L, all P < 0.001. A total of 3 symptomatic hypoglycemic episodes
were reported. No significant reductions in body weight were observed. The mean daily dose of insulin decreased by
14 U between week 0 (30.20 ± 9.93 U) and week 20 (16.38 ± 5.15 U). The total treatment satisfaction score showed a
significant increase from study baseline to end point. Significant increases in SOD(90.00 ± 16.62 to 108.81 ± 27.02 u/ml,
P < 0.01) and reductions in 8-iso-PG(2.15 ± 0.61 to 1.64 ± 0.42 pg/ml, P < 0.05) were observed between the start and
end of the observation period. There were significant differences in baseline HbA1c, duration of diabetes, and baseline
postprandial C-peptide between the A1c≤ 6.5% group and the A1c > 7.0% group [HbA1c: 7.25% ± 1.02% vs. 9.32% ±
1.23%; duration: 7.84 ± 1.02 vs. 13.96 ± 1.35 years; postprandial C-peptide: 4.83 ± 2.11 vs 2.54 ± 0.87 nmol/L, all P < 0.05].
Conclusions: The observational study shows that, in T2DM patients inadequately controlled with premixed insulin,
switching therapy to glargine plus OADs is associated with significant improvements in glycaemic control and
treatment satisfaction, and is with low incidence of hypoglycemia. Baseline postprandial C-peptide, HbA1c, and
duration of diabetes are the key factors closely related to efficacy of this treatment regimen.
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Type-2 diabetes mellitus (T2DM) is a progressive condition
in which the level of glycated hemoglobin rises inexorably
over time, and the function of beta cells declines. If lifestyle
interventions and oral anti-diabetes drugs (OADs) prove
inadequate in controlling glycemic levels, insulin therapy
becomes necessary.
Until recently, opinion on how, or when, to start insu-
lin treatment in T2DM was divided, and initial insulin
treatment regimens are known to vary between different
countries. Professional diabetes organizations recommend
that basal or premixed insulin could be used as the initial
insulin therapy. The basal insulin analogue glargine has
a long duration of action (approximately 24 h), with little
or no discernible peak in blood insulin concentration, and
a lower rate of hypoglycemia. Combination therapy of
OHA with basal insulin can be regarded as an effective
first choice method for introducing insulin in a stepwise
approach, adapting to the progressive β-cell failure [1].
Indeed, in China, many patients use premixed insulin
as the initial insulin therapy, in part because premixed
insulin has come to the market earlier, and is considerably
cheaper than basal insulin analogs. Premixed insulin
usually contains a rapid-acting insulin combined with
an intermediate-acting insulin to mimic endogenous
insulin secretion patterns, and is taken once or twice
daily, normally before breakfast and dinner. The use of
premixed insulin therapy could therefore result in a
clinically relevant improvement in a patient’s glycated
hemoglobin level. However, premixed insulin alone can
be insufficient to achieve and sustain optimal glycemic
control, and there are often additional concerns regarding
hypoglycemia, weight gain, and lifestyle restrictions [2].
Moreover, there is limited information available regarding
therapeutic options for patients for who premixed insulin
provides inadequate glycemic control, who frequently
experience episodes of hypoglycemia or those who want
to avoid additional injections.
A currently favored hypothesis is that oxidative stress,
through a single unifying mechanism of superoxide
production, is the common pathogenic factor leading
to insulin resistance, β-cell dysfunction, and T2DM [3].
Hyperglycemia and fluctuating blood glucose concentra-
tions may also contribute to oxidative stress [4]. Therapies
aimed at reducing oxidative stress may therefore benefit
patients with T2DM.
A 12-week study in German [5] indicated that trans-
ferring patients with T2DM from premixed insulin to once-
daily insulin glargine plus OADs provides a convenient,
safe and effective treatment option that significantly
improves metabolic control. However, whether these
benefits extend to Chinese patients with Type 2 diabetes
in a longer duration of time has yet to be investigated.
In this study, we conducted a clinical trial to evaluatethe efficacy and safety of insulin glargine with concomitant
OADs in patients with T2DM who were previously sub-
optimally controlled on premixed insulin therapies. The
primary objective was to compare the change in A1c from
baseline to endpoint (week 20). In addition, secondary
objectives included the percentage of participants who
achieved A1c of 6.5-7.0% or less, the number of hypo-
glycemic events, and the change in body weight, treatment
satisfaction, and changes in biomarkers of oxidative stress.
Furthermore, the study evaluated potential patient charac-
teristics that may aid in identifying individuals who will
benefit most from such a switch in regimens.
Research design and methods
Patients
The patients with a T2DM duration of at least one year
were enrolled in the Endocrinology Department of the
Third Affiliated Hospital of Guangzhou Medical University
between Nov 2010 to Mar 2012. These patients, aged
18–75 years, were being treated with a stable dose of
human or analogue premixed insulin (the most frequently
prescribed ratios were 25/75 and 30/70), without oral
hypoglycemic drugs, for at least 3 months. Further inclu-
sion criteria included HbA1c levels between 7.5 and
10.0%. The decision to use a therapy regimen including
insulin glargine with OADs was at the discretion of the
physicians and patients, and depended partly on subjective
parameters, including lack of efficacy of premixed insulin,
the patient wanting a more flexible lifestyle, frequent
occurrence of hypoglycemia with previous therapy, and
lack of tolerance of the previous therapy. Exclusion criteria
were according to the indications and contra-indications
(such as patients hypersensitive to insulin glargine or any
of the excipients) given in the prescribing information
and summary of product characteristics for insulin
glargine, patients treated with steroid or nonsteroidal
anti-inflammatory drugs, patients who had experienced
an acute concurrent illness during the 3-month period
preceding the investigation, acute diabetic complications
(such as diabetic ketoacidosis or hyperosmolar non-ketotic
coma), severe chronic diabetic complications, and severe
intercurrent illness. Additional exclusion criteria were
sight-threatening retinopathy, a plasma creatinine level
of 1.47 mg/dl (130 μmol/L) or more, cardiac disease (a
history of unstable angina or myocardial infarction within
the previous 6 months, or New York Heart Association
class III or IV congestive heart failure), uncontrolled
hypertension (systolic pressure ≥180 mmHg or diastolic
pressure ≥105 mmHg), hepatic disease, an alanine ami-
notransferase level at least twice the upper limit of the
normal range, tumors, and the likelihood of pregnancy.
The study was conducted in accordance with the
declaration of Helsinki and Good Clinical Practice
guidelines. Before study entry, all participants were
Zhang et al. Diabetology & Metabolic Syndrome 2014, 6:37 Page 3 of 7
http://www.dmsjournal.com/content/6/1/37willing to perform glucose self-monitoring, and all patients
gave written informed consent.Study design
This 20-week trial was an open-label, non-interventional,
observational study. At the start of the observation
period, patients were given insulin glargine (Lantus,
Sanofi–Aventis, Shanghai, China) to be administered
once daily via subcutaneous injection; dosing decisions
and concomitant OAD therapy (dosage, type and changes
where necessary) were at the discretion of the physician.
After the initial visit (week 0, start of observation), sub-
sequent visits were scheduled at weeks 2, 4, 8, 12, 16 and
20 (end of observation), with interim telephone contact.
Self-monitored blood glucose (SMBG) was performed
using the patients’ own BG meter (Optium Xceed, Abbott).
Physicians gave all patients training to ensure they could
perform SMBG correctly and accurately. Before each visit
and telephone contact, patients were asked to perform
three capillary glucose profiles obtained before meals,
2 hours after eating, and at bedtime.
The trial-management system estimated initial doses of
glargine according to the following formulae: for patients
with an A1c < 8%, the initial doses of glargine was the total
daily dose of premixed insulin × 0.6; for patients with an
A1c ≥ 8%, the starting glargine dose was equal to total
daily dose of premixed insulin × 0.8. During the first
4 weeks of the study, glargine doses were titrated every
3-4 days to reach the glycemic goal. This goal was
defined as a fasting capillary blood glucose of less than
5.5 mmol/L, and capillary blood glucose at 2 h after
each of three meals of less than 8.0 mmol/L. Glargine
doses were adjusted by a forced titration regimen [6]
(presented in Table 1).
During the observation period, blood pressure, heart
rate, waist circumference, and body weight were measured,
while body-mass index (BMI) was calculated at all visits.
HbA1c, fasting C-peptide, 2 hour postprandial C-peptide,
serum superoxide dismutase (SOD), and serum 8-iso-
prostaglandin (8-iso-PG) were measured at the start
and at the end of the observational period. HbA1c was
measured by high-performance liquid chromatography
(Biorad Variant II, Biorad), while serum C-peptide was
assessed by chemilluminescence assay (Immulite, DPC,Table 1 Insulin glargine dose titration algorithm and monitor
Insulin dose titration algorithm If self-monitored fasting BG for 2
> 8.9 mmol/l (> 160 mg/dl)
>7.8 to≤ 8.9 mmol/L(>140 to ≤1
>6.7 to≤ 7.8 mmol/L(>120 to ≤1
>5.5 to≤ 6.7 mmol/L(>100 to ≤1
5.5 mmol/l (≤100 mg/dl)LA, USA). Serum SOD and 8-iso-PG were measured
using enzyme-linked immunosorbent assay (Dako).
Treatment satisfaction was assessed using a diabetes
treatment satisfaction questionnaire(DTSQ)with demon-
strated validity and reliability in diabetic patient popula-
tions. The questions covered current satisfaction with the
treatment, convenience of therapy, treatment flexibility,
diabetes management (including weight), whether or not
this treatment should be recommended to other patients,
and whether to continue with the treatment regimen. Each
factor is scored from 6 to 0 with a higher score indicating
greater satisfaction; the treatment satisfaction score is the
sum of the six items of the DTSQ for each respondent.
Two additional factors measuring the perceived frequency
of hypo- and hyperglycemia are scored from 0 (none of
the time) to 6 (most of the time). DTSQ was administered
at baseline and at end point.
Patients reported adverse events (AEs), including episodes
of hypoglycemia, and adverse drug reactions (ADRs), either
at each visit or at the time of occurrence. Hypoglycemia
was defined as a blood glucose concentration <3.3 mol/L,
with or without symptoms consistent with hypoglycemia.
Hypoglycaemic episodes were defined as having classical
symptoms of hypoglycaemia or blood glucose level below
3.3 mmol/L and prompt recovery after the patient self-
administered carbohydrate. Severe hypoglycemia was
defined either as an event with symptoms consistent
with hypoglycemia, which required assistance, and was
associated with a BG concentration of ≦2.0 mmol/l, or
recovery after oral carbohydrate, intravenous glucose,
or glucagon administration. Nocturnal hypoglycemia was
defined as the occurrence of hypoglycemia while the indi-
vidual was asleep. Whenever a participant awoke during
the night and experienced symptoms of hypoglycemia,
self-monitoring of BG was performed and documented
in the patients’ diary.Statistical analysis
Data were analyzed using the SPSS 11.0 program, and
statistical significance was determined using paired t
test. To analyze the data that are not normally distributed,
logarithmic transformation will be performed. Count
data were analyzed with chi-square test. Significance
was defined as P < 0.05.ing
consecutive days with no severe hypoglycemia:
Add 8 IU/day
60 mg/dl) Add 6 IU/day
40 mg/dl) Add 4 IU/day
20 mg/dl) Add 2 IU/day
No further
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Patients
Of 78 patients who underwent screening, a total of 33
male and 37 female patients were enrolled in to the
observation and completed the study. Age (mean ± SD),
BMI, and duration of diabetes were 59.95 ± 10.21 years,
24.10 ± 3.87 kg/m2, and 7.78 ± 2.95 years, respectively.
Duration of premixed insulin therapy was 3.21 ± 0.87 years.
The breakdown of prior insulin therapies of the patient
population is as follows: 61.43% Humalog Mix 75/25™
(Lilly, USA), 15.71% Humulin70/30 (Lilly, USA), 18.57%
Novomix30 (Novo Nordisk, Denmark), and 4.29% Novo-
lin30R (Novo Nordisk, Denmark). Among the patients,
8 patients treated with premix insulin from diagnosis of
DM, 43 patients initiated insulin after failure of one or
two OADs, 19 patients initiated insulin after failure of
two or three OADs . The most common reasons given
by physicians and patients for switching from premixed
insulin to insulin glargine included lack of efficacy of
premixed insulin (48.57%), the patient wanting a more
flexible lifestyle (50.0%), frequent occurrence of hypo-
glycemia with the previous therapy (17.14%), and lack
of toleration of the previous therapy (14.29%).
Efficacy
Over the 20-week treatment period, reductions in both
BG(FBG, 2 h PBG)and HbA1c levels were observed.
Mean (±SD) HbA1c levels decreased from 8.28 ± 1.24%
to 6.83 ± 1.09%, mean (±SD) FBG levels decreased from
7.64 ± 1.36 mmol/L to 5.57 ± 1.21 mmol/L, and mean
2 hour PBG levels decreased from 12.07 ± 1.17 mmol/L
to 8.94 ± 1.56 mmol/L. In total, 52 (74.29%) patients
reached their target FBG levels of 4.1–5.5 mmol/l, while
44 (62.86%) patients achieved the target 2 h PBG level
of 7.2–8.9 mmol/l. Compared with baseline, 56 (80.0%)
patients obtained hemoglobin A1c concentration of 7%
or less (Figure 1).
Safety
During the 20-week treatment period, a total of 3 symp-
tomatic hypoglycemic episodes were reported in 2 patientsFigure 1 Proportion of patients who achieved clinically relevant
changes in FBG (4.1–5.5 mmol/l), 2 h PBG (7.2–8.9 mmol/l), or
HbA1c (< 7.0%) target at week 20. * P < 0.001 vs. baseline.at 2 hours after breakfast. The lowest blood glucose level
was 3.2 mmol/L. There were no nocturnal or severe
hypoglycemia events reported.
Body weight
A non-significant reduction in body weight was observed
between the baseline and end of the observation period.
Mean (±SD) body weight decreased from 61.19 ± 9.29 kg
to 60.07 ± 9.16 kg (P >0.05), and BMI was stable at both
baseline and the final visit.
Insulin dose and oral anti-diabetic therapy
The mean daily dose of insulin decreased by 14 U between
week 0 (30.20 ± 9.93 U) and week 20 (16.38 ± 5.15 U). At
baseline, all patients were treated with premixed alone,
while at the endpoint all patients were treated with insulin
glargine and OADs. Among the OADs used, most patients
(82.86% [n = 58]) received a single drug, while the rest
(17.14% [n = 12]) received 2 oral combination therapies.
Metformin, glimepiride, glibenclamide, and α-glucosidase
inhibitors were used most frequently.
Patient satisfaction
The total treatment satisfaction score (DTSQ score)
showed a significant increase from baseline to end point
during treatment with glargine +OAD, increasing from
27.12 ± 4.29 to 32.07 ± 5.16 (P <0.05). Patients were found
to significantly favor the switched treatment for five of
six items in the treatment satisfaction scale: current
satisfaction with treatment (3.4 ± 0.8 vs. 5.1 ± 0.5; P <0.01),
convenience of treatment (3.1 ± 0.5 vs. 4.9 ± 0.2; P < 0.01),
flexibility of treatment (2.9 ± 0.5 vs. 5.2 ± 0.4; P <0.01), rec-
ommend to others (3.3 ± 0.8 vs. 5.0 ± 0.2; P < 0.01), and
satisfaction to continue current treatment (3.4 ± 0.9 vs.
5.2 ± 0.4; P <0.01). No significantly changes in scores of
diabetes management (including weight) were recorded
(4.7 ± 0.4 vs. 4.5 ± 0.6, P > 0.05). Moreover, the DTSQ
showed a decrease in perceived frequency of hypoglycemia
(3.4 ± 0.2 vs. 0.8 ± 0.3, P < 0.01) and hyperglycemia (3.2 ±
0.7 vs. 1.5 ± 0.3, P < 0.01) during the observation period.
Identification of factors associated with reaching target
HbA1c values
Differences between the patient groups who did and did
not reach HbA1c targets (A1C ≤ 6.5%, 6.5% <A1C <7% or
A1C >7.0%) by study end were compared. The age, BMI,
weight,WHR,fasting C-peptide at baseline, and premixed
insulin dose were similar between the three groups. The
duration of diabetes was significantly longer in A1C > 7.0%
group than in the A1C ≤ 6.5% group (P < 0.01), and the
level of baseline HbA1c, baseline 2-hour postprandial
C-peptide were significantly higher in A1C > 7.0% group
than in the A1C ≤ 6.5% group (P < 0.01). The A1C ≤ 6.5%
group had shorter duration of diabetes, higher baseline 2-
Table 3 Comparison of serum SOD and 8-iso-PG between
baseline and endpoint
Baseline Endpoint P
SOD(u/ml) 90.00 ± 16.62 108.81 ± 27.02 0.009
8-iso-PG (pg/ml) 2.15 ± 0.61 1.641 ± 0.42 0.012
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20 weeks treatment, the poorly controlled group (A1C >
7.0% at end point) had a more marked reduction in
HbA1c. The two OADs combination therapies was more
frequently used in the A1C > 7.0% group (A1C ≤ 6.5%
group n = 0; A1C > 7.0% group n = 10; P = 0.000) Table 2.
Changes in markers of oxidative stress
Over the 20-week treatment period, significant increases
in serum SOD, and significant reductions in serum 8-iso-
PG were observed (Table 3).
Discussion
Here, we describe a non-interventional, non-randomized
observational study that was undertaken to document
the experience of transferring patients with T2DM from
premixed insulin, to insulin glargine.
Several barriers exist for the initiation and subsequent
optimization of insulin therapy, including the risk of
hypoglycemia, weight gain, and concerns about daily
injections and/or restrictions to lifestyle [7-9]. Ideally,
an insulin regimen should be matched to the individual
patient, considering his or her lifestyle needs and physical
and mental capabilities. At the point of initiation of insulin
treatment alone, the guidance and information provided
varies significantly. AACE recommendations state that any
one of the four different approaches to insulin initiation
may be used, including a once-daily basal insulin regimen,
a premixed insulin preparation that can be administeredTable 2 Baseline characteristics, clinical presentation, with di
Characteristic ≤6.5%
Number 16
age(yr) 58.31 ± 7.21
Duration of diabetes(yr) 7.84 ± 1.02
Baseline BMI(kg/m2) 24.11 ± 3.34
Baseline weight (kg) 61.35 ± 8.76
Baseline WHR 0.89 ± 0.09
Baseline HbA1c(%) 7.25 ± 1.02
Baseline fasting C-peptide 1.82 ± 0.65
Baseline 2-h postprandial C-peptide 4.83 ± 2.11
Baseline premixed insulin dose(U/d) 30.50 ± 4.12
HbA1c change from baseline 0.82 ± 0.10







*P < 0.01 ; #P < 0.05, HbA1c > 7% group vs. HbA1c ≤ 6.5% group.once or twice daily, a basal-bolus regimen, or a prandial
regimen [10]. The published joint position statements
from the ADA and EASD, however, only recommend the
use of basal insulin in the first instance [11]. However in
China, the use of premixed insulin as the initial insulin
treatment is a popular option. We therefore set out to
determine it is possible to improve treatment efficacy
in the patients who were poorly controlled with premixed
insulin, using basal insulin glargine +OADs.
Our study demonstrated that initiation of insulin glargine
with OADs improves glycemic control in patients with
T2DM who were poorly controlled with premixed insulin
prior to the observation period. Patients were enrolled for
varying reasons including lack of efficacy of premixed insu-
lin (7% <HbA1c < 10%), wanting a more flexible lifestyle,
frequent occurrence of hypoglycemia with previous therapy,
and lack of tolerability of the previous therapy. During the
20 weeks of observation, significant improvements in both
HbA1c and BG were observed. Furthermore, the daily insu-
lin dose was decreased with no significant variation in body
weight. Three episodes of symptomatic hypoglycemia oc-
curred, but there were no episodes of severe hypoglycemia.fferent controlled glycemia
Between 6.5% and 7% >7% P
39 15
59.30 ± 6.87 57.33 ± 8.23 0.652
8.01 ± 0.97 13.96 ± 1.35 0.012#
24.87 ± 3.56 23.98 ± 4.56 0.143
60.04 ± 9.13 58.23 ± 3.58 0.087
0.90 ± 0.12 0.86 ± 0.15 0.321
8.11 ± 0.85 9.32 ± 1.23 0.028#
1.87 ± 0.78 1.84 ± 0.53 0.083
3.89 ± 1.15 2.54 ± 0.87 0.034#
30.23 ± 7.65 33.87 ± 8.21 0.056
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fixed-ratio mixtures, with a percentage of rapid-acting
insulin available for prandial phases, and the remainder
of the mixture consisting of a protamine suspension of
the insulin analog for basal periods. Randomized trials
directly comparing the initiation of insulin therapy between
basal and premixed analogues are scarce. The 4 T study
compared three different insulin regimens: basal insulin
once daily, premixed insulin twice daily or prandial insulin
thrice daily. In this study the HbA1c at the end of the first
year was similarly, the rates of hypoglycemia was lowest
in the basal insulin group [12]. During the subsequent
2-year study extension, there was no statistical difference
in the mean HbA1c among the three groups. Based on
lower overall rates of minor hypoglycemia, reduced weight
gain, and perceived convenience, the authors of this study
recommended once-daily basal insulin as the first-line
insulin therapy [13]. Janka et al. demonstrated that basal
insulin glargine once daily, with glimepiride plus metformin
treatment, was safer and more effective than beginning
twice-daily injections of 70/30 and discontinuing OADs
in type 2 diabetic patients inadequately controlled with
OADs [14]. In a 12 week observational study of every-
day clinical practice, Harmer et al. have shown that
once daily insulin glargine plus OADs is an effective
therapeutic regimen with a good safety profile for
patients with T2DM who were inadequately controlled
with premixed insulin [5]. A recent systematic review
and meta-analysis of basal and premixed regimens
demonstrated that twice-daily premixed insulin regimens
reduced HbA1c by an additional 0.45% (CI 0.19–0.70%),
but with additional weight gain and higher rates of
hypoglycemia [15].
Glargine is a long-acting basal insulin analogue that has
proved superior to NPH insulin for the management of
T2DM. It can achieve a peakless level for at least 24 hours,
so is associated with a lower risk of hypoglycaemia.
This is of particular interest because fears of hypoglycemia
remains one of the key obstacles to both initiating and
optimizing insulin therapy. Premixed insulins are pre-
made combinations of NPH and short-acting insulins.
The action profile of NPH features a slightly higher peak
than those of long-acting analogs. This increases the risk
for hypoglycemia, especially interprandial and nocturnal
hypoglycaemia, thus hindering the achievement of good
metabolic control [16-18].
Before the switching treatment, all patients were treated
with premixed insulin alone, and at the end of the study,
all patients were treated with insulin glargine and OADs.
It should be stressed that the amount of premixed insulin
was not large ( approx. 30 IU/day) and patients have not
been treated with OAD before switching. After switching,
the use of OADs may contribute to achieving adequate
glycemic control through different mechanisms.Slight reductions in body weight were observed between
the start and end of the observation period. Insulin is a
growth-promoting hormone that promotes the storage of
essential nutrients, including fats. A potential side effect of
weight gain from insulin treatment can be troublesome,
and can also promote insulin resistance, result in poorly
controlled diabetes. In this study, the mean daily dose of
insulin decreased by 14 U between week 0 and week 20,
which may have contributed to the weight loss and
well-controlled BG.
The basal insulin regimen was associated with a greater
improvement in quality of life and treatment satisfaction
compared with the previous premixed insulin. Fewer insu-
lin injections with glargine therapy may have contributed
to the greater treatment satisfaction. Other factors, such
as oral medication, may also be involved in improving the
treatment satisfaction. Pharmacological therapy alone is
not enough to guarantee amelioration of patient condition,
and controlling diabetes requires frequent monitoring by
the patient, and for this reason compliance is vital to
achieving euglycemia. The choice of any regimen depends
to a large degree on whether the patient can conform to
the complexity of the regimen over the long term. If
switching a therapy improves patient compliance, it will
lead to more favorable outcomes in diabetes.
When the sub-group of patients switched to glargine
treatment is analyzed specifically, baseline postprandial
C-peptide, HbA1c and diabetes duration are the key factors
that are closely related to treatment success. The UKPDS
has shown that β-cell function progressively deteriorates
over time in patients with T2DM, irrespective of lifestyle
and existing pharmacological interventions. The 2-hour
postprandial C-peptide level represents the insulin response
after a glucose challenge, which was used to assess β-cell-
stimulated insulin secretory capacity. Patients who had
lower HbA1c levels, a shorter duration of DM, and higher
postprandial C-peptide levels had more chance to achieve
glycemic control after switching treatment. For patients
with reduced β-cell stimulated insulin–secretory capacity,
represented by postprandial C-peptide, the benefits of
glargine were limited. Even if majority of patients in the
A1c >7.0% group taking two OADs, blood sugar of the
patients was unsatisfactorily controlled, further prandial
intervention was therefore required in these patients.
At 20 weeks, FBG levels were not significantly different
among the 3 subgroups. However, the morning postpran-
dial glucose, postprandial glucose values at noon and at
dinnertime were statistically higher in the HbA1c > 7.0%
subgroup than in HbA1c < 6.5% subgroup. The decrease
in HbA1c was more obvious in the HbA1c > 7.0% sub-
group than in the HbA1c < 6.5% group. This suggests that
for the patients with poor glycemic control, the therapy
using insulin glargine focused on FBG has a greater
impact on overall glycemic control. The present study
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to glycemic control in patients with mild or moderate
hyperglycemia than in those with poorly controlled
diabetes mellitus, in whom fasting hyperglycemia is the
main contributor to overall hyperglycemia. Fasting hyper-
glycemia is the main contributor to glycemic load if
HbA1c is above 8.5% [19].
Diabetes is characterized by glycemic disorders that
include both sustained chronic hyperglycemia and acute
glucose fluctuations. Oxidative stress, through the produc-
tion of reactive oxygen species (ROS), has been proposed
as the root cause underlying the development of insulin
resistance, β -cell dysfunction, and T2DM [3]. Increased
glycemic variability leads to the generation of more ROS
and, despite having similar HbA1c levels. At present,
most of the interventional trials using the “treat-to-target”
concept have been conducted to achieve near-normal
glucose value at fasting and A1C levels < 7%. Acute glucose
fluctuations have rarely been taken into account. It was
demonstrated that urinary excretion rate of 8-iso-PGF2
and serum 8-iso-PG, serum SOD were correlated with
the glycemic variability and oxidative stress [20]. To
ascertain the changes in oxidative stress during the
switching treatment, the oxidative stress biomarker serum
8-iso-PG and the antioxidative stress biomarker serum
SOD were measured. Through the period of observation
is too short, significant increases in SOD and reductions
in 8-iso-PG were observed between the start and end of
the observation period. This suggests that glargine with
OADs is the ideal regimen, improving glycemic control
while probably minimizing blood glucose fluctuations.
In summary, in this observational study we have shown
that once daily insulin glargine plus OADs is an effective
therapeutic regimen with a good safety profile for patients
with T2DM who were inadequately controlled with pre-
mixed insulin. Baseline postprandial C-peptide, HbA1c
and diabetes duration are the key factors that are closely
related to efficacy of this switching regimen.
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